| Product Name | Grazoprevir - API |
| Product Code | DA-G106-a |
| Chemical name | Grazoprevir |
| Synonyms | (33R,35S,91R,92R,5S)-5-(tert-Butyl)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxamide; Cyclopropanecarboxamide, N-[[[(1R,2R)-2-[5-(3-hydroxy-6-methoxy-2-quinoxalinyl)pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-, cyclic (1→2)-ether, (1R,2S); |
| Impurity | NA |
| CAS Number | 1350514-68-9 |
| Alternate CAS # | NA |
| Molecular form | C38H50N6O9S |
| Appearance | White to Off-White Solid |
| Melting Point | NA |
| Mol. Weight | 766.91 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | pharmaceutical standards,intermediates,Fine Chemicals,metabolites,impurities,chiral standards,enzyme activators,enzyme inhibitors |
| Boiling Point | NA |
| Applications | MK 5172, also known as Grazoprevir, is a second-generation NS3/4A protease inhibitor that is often used in combination with the second-generation NS5A inhibitor, Elbasvir, for the treatment of hepatitis C virus infection. It is a COVID19-related research product. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
